DexCom, Inc. provided revenue guidance for the year 2023. For 2023, Dexcom currently anticipates total revenue of approximately $3.35 billion to $3.49 billion, representing expected growth of approximately 15% to 20% over 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
116.1 USD | +2.70% | +4.71% | -6.47% |
15/07 | Morgan Stanley Cuts Price Target on DexCom to $120 From $132, Keeps Equalweight Rating | MT |
12/07 | Stifel Adjusts Price Target on DexCom to $132 From $145 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.47% | 44.94B | |
-6.68% | 179B | |
-5.20% | 98.84B | |
-5.38% | 65.34B | |
+17.08% | 45.41B | |
+9.74% | 43.76B | |
+14.01% | 29.01B | |
+21.25% | 25.65B | |
-6.53% | 23.32B | |
-11.70% | 21.92B |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- DexCom, Inc. Provides Revenue Guidance for the Year 2023